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In order to elucidate the relative importance of neutralizing determinants on each of the three major adenoviral capsid components, we
have generated chimeric vectors where the hexon protein, or the fiber protein, or both hexon and fiber proteins of one serotype (Simian
Adenovirus 24/Pan 7) have been replaced by those of another (Simian Adenovirus 23/Pan 6). The effect of each replacement was evaluated
by neutralization assays and by attempted vector re-administration into mice. Both hexon and fiber were found to harbor neutralization
epitopes although in vivo transduction was more severely affected by anti-hexon antibodies.
D 2005 Elsevier Inc. All rights reserved.
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Humoral immunity to adenoviruses has emerged as one
of the most important hurdles for gene therapy using
adenoviral vectors. The use of adenoviral gene therapy
vectors based on different non-cross reacting serotypes is
being investigated by several groups as a means to
administer adenoviral vectors, either in a re-administration
setting, or in subjects with circulating antibodies against the
common serotypes such as human adenovirus serotype 5
(Ad5). Early studies designed to determine the adenoviral
capsid components against which neutralizing antibodies
were directed concluded that both group-specific (located on
the hexon protein) and type-specific (located on the fiber
protein) components were responsible for the elicitation of
neutralizing antibodies in rabbits (Wilcox and Ginsberg,
1963), guinea pigs (Kjellen and Pereira, 1968) and humans
(Banks et al., 1966; Kasel et al., 1964). Although the0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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different experimental systems, in most studies, the hexon
was found to be the principal target for neutralizing
antibodies (Gelderblom et al., 1968; Kjellen and Pereira,
1968; Norrby, 1969; Wilcox and Ginsberg, 1963). Several
groups have reported that purified fiber does not cause the
elicitation of neutralizing antibodies (Kjellen and Pereira,
1968; Pettersson et al., 1968; Wadell, 1972). Also, Mautner
and Willcox (1974) noted that the amount of purified fiber
or hexon immunogen that is required for mice to produce
neutralizing antibodies is considerably higher than that
required when the intact adenovirus is used, indicating that
the trimeric forms of the hexon and fiber present neutraliza-
tion domains that may be difficult to reconstitute using
purified capsid proteins and may not accurately reflect the
response to an infection with the intact virus. The minor
capsid components such as pIX, IIIa, pVI, and pVIII have
not been shown to elicit the production of neutralizing
antibodies.
Because gene therapy protocols frequently require re-
administration, and because serotype-specific anti-adenovi-
ral antibodies have been shown to preclude efficacious05) 207–214
Rapid Communication208administration of adenoviral vectors, recent efforts have
been directed towards engineering the capsid as a means to
generating vectors that may evade the neutralizing anti-
bodies generated either as a result of the first gene therapy
administration, or due to previous natural infections (Gall et
al., 1996, 1998; Roy et al., 1998; Wu et al., 2002; Youil et
al., 2002). We recently described a series of gene therapy
vectors based on subgroup E adenoviruses that were
originally isolated from chimpanzees (Roy et al., 2004a,
2004b). Sequence analysis of Simian Adenovirus 23 and
Simian Adenovirus 24 (hereinafter referred to by their
original names Pan 6 and Pan 7, respectively) showed that
although the two viruses were very closely related (with
greater than 98% similarity at the nucleotide level), the
neutralization domains were distinct in vitro as well as in
vivo (Roy et al., 2004b), that is, antibodies against one did
not neutralize or prevent the administration of the other.
This fact, together with the very high degree of similarity
between the two viruses, prompted us to construct three
chimeric viruses that are artificial crossover recombinants
between Pan 6 and Pan 7, using restriction sites common to
both viruses. Because the three chimeric viruses that were
made harbored different combinations of Pan 6 and Pan 7
penton base, hexon and fiber, the three major adenoviral
capsid components, we have used them to analyze the
contribution of each of the three major capsid proteins in
eliciting antibodies that neutralize the Pan 6 and Pan 7
derived gene therapy vectors.Results and discussion
Construction of chimeric viruses
We constructed three adenovirus vectors that were
chimeric between Pan 6 and Pan 7; the objective of the
constructions was to create adenovirus vectors where the
hexon, the fiber, or both proteins of the Pan 7 derived vector
(C7eGFP) were replaced by those from Pan 6. Utilizing the
restriction sites for the enzymes MluI and SbfI that are
common to both viruses, three crossover recombinants,
C776eGFP, C766eGFP, and C767eGFP were constructed as
shown in Fig. 1. (The numbers in the nomenclature indicate
the origin of the chimpanzee adenovirus serotype – Pan 6 or
Pan 7 – from which the penton base, hexon, and fiber genes,
respectively, are derived). The MluI site is located near the
C-terminus of the coding region for penton base. Because
there are no differences between Pan 6 and Pan 7 in the
amino-acid sequences of the penton base that are C-terminal
to the MluI site, the penton base amino-acid sequence in all
three chimeric adenoviruses is identical to that in Pan 7 and
the derived vector C7eGFP. The SbfI site is located within
the coding region for the single-stranded DNA binding
protein – DBP – which is coded on the l-strand. In both Pan
6 and Pan 7, DBP is 512 amino acids long with an overall
98.2% sequence identity; only two amino acid differencesexist in the C-terminal 284 residues of DBP sequence to the
left of the SbfI site. Thus, construction of the three chimeric
adenoviruses resulted in a shuffling of the viral coding
regions including the three major capsid proteins, penton
base, hexon and fiber; known to harbor the principal
neutralization determinants. It is likely that we could easily
construct recombinants between the Pan 6 and Pan 7 vectors
because they are very closely related, with over 98%
sequence identity at the nucleotide level (for comparison,
the closely related human adenovirus serotypes 2 and 5
show about a 94% sequence identity). Thus, the proteins
pIX, IVa2, pre-terminal protein, DNA polymerase, 52 K,
pIIIa and penton base that map to the left of theMluI site are
about 99% identical between the two viruses. The proteins
(other than hexon) that map between theMluI and SbfI sites,
pVII, V, Mu, VI, and Endoprotease, show between 98% and
100% sequence identity. The only structural protein (other
than fiber) that maps to the right of the SbfI site is pVIII,
which shows greater than 99% identity. The non-structural
proteins 100 K scaffolding protein and DBP (as mentioned
above) are over 98% identical. This extensive sequence
similarity between Pan 6 and Pan 7 also holds true for most
of the early regulatory proteins present in the E3 and E4
regions, the notable exceptions being the products of the
4th, 5th and 6th open reading frames of the E3 region (Roy
et al., 2004a) which show 48%, 87%, and 67% homology,
respectively. The overall degree of sequence identity at the
nucleotide level between Pan 6 and Pan 7 is indicated as a
co-linear plot in Fig. 1; as discussed above with regard to
amino-acid sequence homology, the only notable divergence
in sequence among capsid proteins is observed within hexon
and fiber coding regions.
Neutralization of chimeric adenoviruses with polyclonal
antisera
We have previously reported (Roy et al., 2004b) that
there was no heterologous cross-neutralization observed
between the adenoviruses Pan 6 and Pan 7 using high-titer
rabbit polyclonal antisera, indicating that the two viruses
were distinct serotypes. The polyclonal rabbit antiserum that
had been raised against the Pan 6 adenovirus neutralized
(i.e., 50% reduction in transduction) the cognate vector
C6eGFP at a dilution that was in the order of 105 (Fig. 2,
upper graph). This antiserum failed to neutralize the Pan 7-
derived vector C7eGFP. The neutralization curves for the
two chimeric adenoviruses that harbored the Pan 6 hexon,
C767eGFP and C766eGFP, were not different from that for
C6eGFP indicating the importance of the hexon epitopes for
neutralization. The chimeric adenovirus C776eGFP that
harbored the Pan 7 hexon and the Pan 6 fiber protein was
also neutralized by the anti-Pan 6 antiserum, albeit at a
concentration that was a log higher than that required for the
adenoviruses that harbored a Pan 6 hexon. Neutralization of
the chimeric adenoviruses with the rabbit anti-Pan 7
antiserum (Fig. 2, lower graph) re-affirmed the importance
Fig. 1. Construction of chimeric vectors. A map of the genome of the vector C7eGFP with the locations of the principal adenoviral protein coding regions is
shown. The positions of the restriction enzyme sites forMluI and SbfI where artificial crossover recombination was carried out is indicated. The contribution to
each of the three chimeric adenoviruses (C776eGFP, C766eGFP, and C767eGFP) from Pan 7 is indicated in blue and that from Pan 6 is shown in red. The
numbers in the nomenclature of the chimeric adenoviruses denotes the parental source of the penton base, hexon and fiber proteins, respectively. The overall
similarity of the complete Pan 6 nucleotide sequence with that of Pan 7 is shown in the similarity plot. The alignment was done by the neighbor-joining method
with Kimura’s 2 parameter correction. The plot was generated using the Simplot software in a sliding window size of 100 bases and moving in steps of 20
bases. The plot is co-linear with the map of C7eGFP except for the E1 region which is shown in the plot but is absent from the vectors. 
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possessed the Pan 7 hexon, C7eGFP and C776eGFP,
yielded similar neutralization curves against the anti-Pan 7
antiserum. The presence of the cognate fiber in C767eGFP
was sufficient to render the chimeric adenovirus susceptible
to neutralization by the anti-Pan 7 antiserum; the neutral-
ization curve was very close to that observed for C7eGFP
and C776eGFP. Also, this anti-Pan 7 antiserum possessed
low-level cross-neutralizing activity against C6eGFP. Theneutralization curves for C6eGFP and C766eGFP were very
similar to one another, as well.
Re-administration of chimeric vectors
We further examined the relative contributions of the
principal capsid components in preventing re-administration
of adenoviral vectors in vivo by testing the transducing
ability of the chimeric adenoviruses in BALB/c mice
Fig. 3. Effect of pre-existing immunity on re-administration with chimeric
vectors. Total liver DNAwas isolated from liver pieces harvested from mice
that had been administered the GFP expressing vector as indicated. The
number of copies of GFP as measured by real-time PCR in each group of
mice is shown. The bars represent standard deviations from the mean of
data obtained from five mice.
Fig. 2. Serial two-fold dilutions of anti-Pan 6 antiserum from a rabbit im-
munized with C6LacZ (upper graph) or anti-Pan 7 antiserum from a rabbit
immunized with C7LacZ (lower graph) were used to neutralize the ade-
novirus vectors C7eGFP, C6eGFP or the artificial crossover recombinants
C776eGFP, C767eGFP or C776eGFP as described in the text. The ade-
novirus neutralization at each antiserum dilution was determined by record-
ing the percent transduction of cells in culture as measured by GFP fluor-
escence using a fluorimeter and plotted against the logarithm of the dilution.
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order to do this, we chose to immunize mice by intra-
muscular administration of the C6LacZ or the C7LacZ
vector and to challenge the mice 4 weeks later by
administering C6eGFP, C7eGFP, or the chimeric vectors
C776eGFP, C766eGFP, and C767eGFP, respectively. We
have previously shown that immunization of mice to
adenoviral capsid proteins is efficiently achieved by intra-
muscular injection of vector and that the resulting immune
response prevents re-administration of a vector of the same
serotype by the intra-venous route (Roy et al., 2004b).
Immunization by the intra-muscular route results in minimal
liver transduction and helps preserve the liver architecture
for the assessment of re-administration efficiency. Also,
because the administration of adenoviral vectors by tail-vein
injections results in a fairly homogeneous transduction of
the liver, a sampling of different portions of the same liver
can be done for the determination of transduction by
microscopy or by the determination of eGFP DNA copy
number. Twenty-five 4-week-old female BALB/c mice ineach of two groups were immunized with either Pan 6 or
Pan 7 vectors (C6LacZ and C7LacZ, respectively) by
administering 1010 viral particles intramuscularly to the
hind limbs. Three weeks later, systemic re-administration
was attempted in each of the two immunized groups by tail-
vein injection of 1011 viral particles of C6eGFP, C7eGFP, as
well as each of the three chimeric vectors C776eGFP,
C767eGFP and C766eGFP (5 mice per vector in each
group). A third group of 25 naive mice was also
administered vector in an identical manner (five mice per
vector) to serve as positive controls for liver transduction.
Because it is known that most of an intravenously
administered adenoviral vector is eliminated in the imme-
diate period following injection and does not contribute
towards transduction (Worgall et al., 1997), we waited 3
days before the livers were harvested for DNA extraction
and for examination by microscopy. Also, this time point is
likely to be too early for any reduction in transduction due
to T-cell-mediated elimination of transduced hepatocytes
following residual vector backbone gene expression. Total
liver cellular DNA was extracted, and quantification of
transduction carried out by real-time quantitative PCR using
primers specific for the GFP transgene. The results are
shown in Fig. 3. Clearly, re-administration was completely
successful using either C7eGFP or C6eGFP when the prior
immunizing virus was not of the same serotype, whereas the
attempted re-administration into mice previously immu-
nized with the same serotype resulted in 4-fold (C7eGFP) to
12-fold (C6eGFP) lower liver DNA levels. The chimeric
vector C766eGFP, that harbors the same hexon and fiber
genes as C6eGFP, behaved similarly to C6eGFP in that pre-
existing immunity to Pan 7 did not affect gene transfer
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reduction in gene transfer. The lack of inhibition of
C766eGFP by pre-existing immunity to Pan 7 indicates
that in this model, the penton base does not contribute
significantly towards providing neutralization epitopes.
Interestingly, gene transfer with the C776eGFP vector
harboring the Pan 7 hexon and the Pan 6 fiber proteins
was only reduced 2-fold in mice that had been previously
immunized with C7LacZ (P = 0.058) but not affected by
prior immunization with C6LacZ. Thus, in this case, pre-
existing immunity to hexon alone reduced transduction
efficiency with C776eGFP but not as much as when
immunity to both hexon and fiber was present. This result
contrasts with that seen using the C767eGFP vector where
antibodies to hexon alone resulted in a large reduction of
transduction.
The BALB/c mice appeared to have mounted a weaker
antibody response to the Pan 7 vector C7LacZ than they did
to the Pan 6 vector C6LacZ as evidenced by the
observation that residual eGFP DNA copy numbers
following re-administration tended to be higher in the Pan
7-immunized mice than the Pan 6-immunized mice in each
instance where re-administration was seen to be unsuccess-
ful. While it is possible that Pan 7-based vectors are less
immunogenic than Pan 6 vectors, it is also possible that this
observation is an artifact of using an inbred mouse strain
where the antibody response to particular antigens can be
idiosyncratic.
In order to qualitatively verify that the liver transduction
data as inferred by quantitative PCR of GFP DNA in total
DNA was in fact representative of actual hepatocyte
transduction, sections of liver from two mice from each
group were microscopically examined for GFP fluores-
cence. Representative fields from each group are shown in
Fig. 4. The transduction efficiency in each experimental
group, as determined by the observation of GFP fluores-Fig. 4. Expression of GFP in liver sections as observed by fluorescence microscop
(middle row) or with a C6LacZ vector (bottom row) were administered one of the
are shown from one of two mice from each group that were harvested for sectioncence, was seen to be in concordance with the quantitative
PCR results. We also did not observe any evidence of an
influx of inflammatory cells in the liver sections in any of
the livers, indicating that at there was little or no cell-
mediated response against residual backbone gene expres-
sion (at the 3-day post administration time point) to
contribute towards absence of expression in mice where
transduction was low.
Contribution of penton base epitopes for neutralization
Although anti-penton base antibodies have been pre-
viously shown not to be important for neutralization
(Wadell, 1972), they have been implicated in amplifying
the effectiveness of anti-fiber antibodies (Gahery-Segard et
al., 1998). Moreover, Fab fragments of antibodies that
bind to the penton base RGD motif, which is known to be
involved in binding cell surface integrins, have been
shown to be able to obstruct virus internalization,
although whole antibodies may be sterically hindered by
the fiber shaft from allowing effective blocking (Nemerow
and Stewart, 2001). The amino-acid sequence of the
penton base protein of the adenovirus Pan 6 differs from
that of Pan 7 at only 9 positions, of which 4 are
conservative, along its 531 residue length. However, in
spite of this high degree of sequence similarity, the fact
that we have observed no evidence of cross-neutralization
between Pan 6 and Pan 7 vectors in vitro or in re-
administration experiments (Roy et al., 2004b) would
appear to support the lack of a significant contribution of
the penton base protein in providing neutralization
determinants. This was confirmed by the observation that
the in vitro neutralization profiles of C6eGFP and
C766eGFP, which share hexon and fiber but possess
penton bases derived from the different serotypes, were
similar; they also behaved in a similar manner in vivo.y. NaRve BALB/c mice (top row), or mice immunized with a C7LacZ vector
five GFP expressing vectors as indicated in columns. Representative fields
ing and microscopy.
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base antibodies for neutralization.
Contribution of fiber epitopes for neutralization
Previous studies using chimeric adenoviruses have
addressed the relevance of neutralization epitopes on the
fiber for preventing re-administration of adenoviral vectors.
Gall et al. (1996) found that Sprague–Dawley rats immu-
nized with an Ad5 vector could not be re-administered an
Ad5 chimeric adenovirus, where the fiber had been replaced
by one from Ad7. The behavior of this chimeric adenovirus
was identical to an Ad5 vector as far as the lack of
successful re-administration was concerned, and the authors
opined that under standard re-administration conditions,
anti-fiber antibodies were inconsequential. This was also
addressed indirectly by Roy et al. (1998) and Wu et al.
(2002) who were able to re-administer to C57BL/6 mice
after altering the serotype of only the hexon component of
an Ad5 vector to that of Ad12 or Ad7, respectively,
suggesting that alteration of neutralization domains of the
hexon alone might result in successful re-administration. We
show here that BALB/c mice immunized with the C6LacZ
vector can be re-administered with the C776eGFP vector,
that is, presence of the Pan 6 fiber alone did not reduce
transduction efficiency. The reciprocal experiment, that is,
transduction with a vector harboring the Pan 7 fiber –
C767eGFP – in the presence of anti-Pan 7 immunity tended
to be less efficient than in naRve animals suggesting some
attenuation of transduction efficiency; however, this differ-
ence did not reach statistical significance (P = 0.3). It is
interesting to note that although substantial transduction
could be achieved by C776eGFP in the presence anti-Pan 6
immunity, the in vitro neutralization curve (Fig. 2, upper
graph) showed good neutralization of this chimeric vector
by the rabbit anti-Pan 6 antiserum, albeit at an 8-fold higher
concentration than that required to neutralize C6eGFP.
Similarly, the in vitro neutralization of C767eGFP with
the rabbit anti-Pan 7 antiserum (Fig. 2, lower graph) was
very efficient. Thus, in the case of C776eGFP and
C767eGFP, the in vitro neutralization data with anti-Pan 6
and anti-Pan 7 antisera, respectively, did not reliably predict
the transduction efficiencies of these two vectors in the
presence of pre-existing immunity to Pan 6 and Pan 7,
respectively.
Contribution of hexon epitopes for neutralization
The importance of the hexon protein in providing
neutralization determinants was evident in the in vitro
neutralization data for C6eGFP and C767eGFP, which
share a hexon protein but not penton base or fiber proteins
(Fig. 2, upper graph). The anti Pan 6 rabbit antiserum that
did not neutralize C7eGFP was able to neutralize
C767eGFP as efficiently as it did C6eGFP, that is, a
50% reduction of transduction could be achieved in eithercase at a tested dilution of 1/163480. Furthermore,
C6eGFP and C767eGFP were equally impaired with
respect to in vivo transduction in the presence of immunity
to Pan 6 vectors (Fig. 3). Similarly, replacement of the
fiber protein from C7eGFP with that from Pan 6 in
C776eGFP did not result in a detectable difference in
neutralization in vitro (Fig 2, lower graph) or improvement
in transduction efficiency in the presence of immunity to
Pan 7 vectors (Fig. 3).
We have previously shown that gene therapy vectors
constructed from the two chimpanzee derived adenoviruses
Pan 6 and Pan 7 can be can be administered to mice, one
following the other, without loss of transduction efficacy
(Roy et al., 2004b). This indicated that neutralization
epitopes were not shared by the two adenovirus serotypes.
In this study, we have utilized the fact that Pan 6 and Pan 7
are closely enough related that it is possible to readily create
artificial recombinants between the two. This allowed us to
construct recombinants where the penton base, hexon and
fiber moieties of the two adenoviruses could be recombined,
allowing an appraisal of the contributions of the major
capsid antigens in providing neutralization determinants. In
vitro neutralization experiments with high titer rabbit
antisera verified that both hexon and fiber proteins harbor
neutralization determinants. While determinants present of
the hexon protein were of paramount importance for
preventing re-administration in BALB/c mice, successful
re-administration in the presence of anti-fiber antibodies was
only sporadic, suggesting that re-administration strategies
based on hexon change alone are unlikely to be consistently
successful.Materials and methods
Construction of chimeric viruses
The construction of E1 deleted vectors based on the
chimpanzee-derived adenoviruses Pan 6 and Pan 7 has been
described (Roy et al., 2004b). All recombinant adenoviruses
were constructed by assembling the complete recombinant
adenoviral genome in a single plasmid where the viral
genome is flanked by PacI sites which were used to release
the recombinant viral genome from the plasmid backbone
prior to transfecting into 293 cells to rescue recombinant
adenovirus. The artificial crossover recombinants were also
first created as plasmids by standard recombinant DNA
techniques utilizing the restriction sites for the enzymes
MluI and SbfI that are common to both viruses and rescued
by transfection into 293 cells. Three crossover recombi-
nants, C776eGFP, C766eGFP, and C767eGFP were con-
structed as shown in Fig. 1. The recombinant adenoviruses
were purified by a standard cesium chloride density gradient
centrifugation method or by the Adenopure kit (Puresyn,
Inc., Malvern, PA). (The Pan 6 genome contains a PacI site
within the E3 region; this was removed from C776eGFP
Rapid Communication 213and C766eGFP by a deletion between the flanking HpaI and
SwaI sites).
In vitro adenovirus neutralization assay
The rabbit antisera raised against either Pan 6 or Pan 7
using the vectors C6LacZ or C7LacZ, respectively (Roy et
al., 2004b) were used to perform neutralization titrations as
described (Roy et al., 2004b). Briefly, each virus under test
was incubated with dilutions of the heat-inactivated
antiserum from immunized rabbits. After a 1-h incubation
at 37 8C, viruses were added to 293 cells in 96 well plates
(at a multiplicity of infection of 104 viral particles per cell)
for 48 h. Expression of GFP was measured by a
FluorImager instrument (Amersham Biosciences, Piscat-
away, NJ) using ImageQuant Software and the percent
reduction of transduced green cells was recorded for each
antiserum dilution and plotted against the logarithm of the
dilution, as shown in Fig. 2.
Immunization of BALB/c mice with adenovirus vectors
The E1 deleted chimpanzee adenoviruses (beta-galacto-
sidase expressing) C6LacZ, or C7LacZ were administered
to 4-week-old BALB/c (Taconic, Germantown, NY) intra-
muscularly at a dose of 1010 viral particles per mouse.
In vivo transduction by adenovirus vectors
The E1 deleted chimpanzee adenoviruses C6eGFP,
C7eGFP and the chimeric vectors C776eGFP, C767eGFP
and C766eGFP carrying the expression cassette of the
Aequorea victoria green fluorescent protein gene driven by
cytomegalovirus (CMV) immediate early promoter (eGFP
cassette) were administered to 7-week-old naRve or pre-
viously immunized BALB/c mice (Taconic, Germantown,
NY), by tail vein injection using a dose of 1011 viral
particles per mouse. The animals were sacrificed 3 days later
for the assessment of gene transfer to the liver by
quantitative real-time PCR or examination of liver sections
by fluorescence microscopy.
Isolation of mouse liver DNA and determination of GFP
copy number by quantitative PCR
About 25 mg of mouse liver was diced into small
pieces and suspended in a Proteinase K digestion buffer
(Buffer ATL from the DNeasy Tissue Kit, Qiagen,
Valencia, CA), digested with proteinase K as recommen-
ded by the manufacturer, extracted with phenol: chloro-
form and the DNA precipitated with ethanol. To determine
GFP copy numbers, 0.5 Ag of the liver DNA was
subjected to real-time quantitative PCR using the primers
AGC AAA GAC CCC AAC GAG AA and GGC GGC
GGT CAC GAA and probing with 6FAM-CGC GAT
CAC ATG GTC CTG CTG G-TAMRA. The linearity ofthe assay was confirmed by running a standard curve for
GFP in parallel using mouse liver genomic DNA spiked
with GFP encoding plasmid DNA. Under the conditions
of the assay, 0.08 copies of GFP per mouse cell (45 pg
DNA) was found to yield a signal about twice the
background.
Analysis of GFP expression in mouse liver by fluorescence
microscopy
Liver tissue from mice was fixed in 10% (v/v) phosphate-
buffered formalin (Protocol, Fisher Scientific, USA) over-
night. The liver pieces were then immersed in a 30% sucrose
solution overnight before sectioning and mounting with
Vectashield with DAPI (Vector Laboratories, Burlingame,
CA) for examination with a fluorescence microscope.Acknowledgments
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